Brickell Biotech Inc

Brickell Biotech — Technical Presentation (October 2021)

18 slides from Brickell Biotech's technical presentation, Oct 7, 2021

  1. Slide 1: Sofpironium Bromide U.S. Phase 3 Pivotal Program Topline Results

    © BrickellBio NASDAC: BBI Sofpironium Bromide U.S. Phase 3 Pivotal Program Topline Results r | Making Fresh Tracks® in Medicine October 7, 2021

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements + This presentation contains forward-looking statements that involve substantial risk and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation other than statements of

  3. Slide 3: Highlights from Today's Announcement

    Highlights from Today's Announcement Brickell announces positive topline results from two U.S. Phase 3 pivotal clinical studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patients* PE ORCTIOUERTIEYE All primary and secondary endpoints were met and achieved statistical signific

  4. Slide 4: U.S. Phase 3 Pivotal Program Overview (Cardigan I & Cardigan II)

    U.S. Phase 3 Pivotal Program Overview (Cardigan | & Cardigan II) STUDY TITLE STUDY DESIGN CO-PRIMARY EFFICACY ENDPOINTS AGREED WITH FDA STUDY POWER CALCULATIONS Multicenter, randomized, double-blinded, vehicle-controlled studies to evaluate the safety and efficacy of topically applied sofpironium br

  5. Slide 5: U.S. Phase 3 Pivotal Program: Subject Disposition

    U.S. Phase 3 Pivotal Program: Subject Disposition Overall, 89% of subjects receiving sofpironium bromide (SB) gel, 15% completed 6 weeks of treatment in the Phase 3 pivotal program CARDIGAN | CARDIGAN II Vehicle Vehicle Total SB Gel, 15% (Placebo Gel) Total SB Gel, 15% (Placebo Gel) (n = 173)? (n =

  6. Slide 6: Co-Primary Efficacy Endpoint: Point Improvement in HDSM-Ax-7

    Co-Primary Efficacy Endpoint: 22 Point Improvement in HDSM-Ax-7 Sofpironium bromide (SB) gel, 15% demonstrated statistically significant HDSM-Ax-7 responses from baseline to EOT CARDIGAN | CARDIGAN II 22 point improvement in HDSM-Ax-7 22 point improvement in HDSM-Ax-7 from baseline to EOT' from base

  7. Slide 7: Co-Primary Efficacy Endpoint: Change in GSP

    Co-Primary Efficacy Endpoint: Change in GSP Sofpironium bromide (SB) gel, 15% demonstrated statistically significant responses compared to vehicle for change in GSP from baseline to EOT CARDIGAN | CARDIGAN II GSP change from baseline to EOT' GSP change from baseline to EOT' Vehicle SB 15% Vehicle SB

  8. Slide 8: Secondary Efficacy Endpoint: Point Improvement in HDSM-Ax-7

    Secondary Efficacy Endpoint: 21 Point Improvement in HDSM-Ax-7 Sofpironium bromide (SB) gel, 15% demonstrated statistically significant HDSM-Ax-7 responses from baseline to EOT CARDIGAN | CARDIGAN II HDSM-Ax-7 reduction (21 point improvement) HDSM-Ax-7 reduction (21 point improvement) from baseline

  9. Slide 9: Secondary Efficacy Endpoint: Combined HDSM-Ax-7 & GSP Analysis

    Secondary Efficacy Endpoint: Combined HDSM-Ax-7 & GSP Analysis Sofpironium bromide (SB) gel, 15% demonstrated statistically significant responses in a combined HDSM-Ax-7 (22 point improvement) and GSP (270% reduction) analysis from baseline to EOT CARDIGAN | CARDIGAN II HDSM-Ax-7 (22 point improveme

  10. Slide 10: Secondary Efficacy Endpoint: Combined HDSM-Ax-7 & GSP Analysis

    Secondary Efficacy Endpoint: Combined HDSM-Ax-7 & GSP Analysis Sofpironium bromide (SB) gel, 15% demonstrated statistically significant responses in a combined HDSM-Ax-7 (21 point improvement) and GSP (250% reduction) analysis from baseline to EOT CARDIGAN | CARDIGAN II HDSM-Ax-7 (21 point improveme

  11. Slide 11: U.S. Phase 3 Pivotal Program: Safety Summary

    U.S. Phase 3 Pivotal Program: Safety Summary Majority of treatment-emergent adverse events (TEAEs) were mild or moderate in severity and transient in nature CARDIGAN | CARDIGAN II SB Gel, 15% (Piacabs Geb SB Gel, 15% (Pincabe Geb (n = 173) (n = 176) (n = 180) (n= 171) Any TEAE, n (%) 62 (35.8%) 23 (

  12. Slide 12: Incidence of Treatment-Emergent Adverse Events (≥2% of Subjects)

    Incidence of Treatment-Emergent Adverse Events (22% of Subjects) Sofpironium bromide (SB) gel, 15% was observed to be generally well tolerated and adverse events were predominantly mild or moderate in severity CARDIGAN | CARDIGAN II Vehicle Vehicle SB Gel, 15% (Placebo Gel) SB Gel, 15% (Placebo Gel)

  13. Slide 13: U.S. Phase 3 Pivotal Program: Conclusions

    U.S. Phase 3 Pivotal Program: Conclusions Cardigan | and Cardigan II results support submission of an NDA to the FDA for sofpironium bromide gel, 15% + Sofpironium bromide gel, 15% resulted in a statistically significant greater proportion of subjects achieving at least a 2-point improvement in HDSM

  14. Slide 14: © BrickellBio

    © BrickellBio

  15. Slide 15: Brickell Biotech, Inc.

    Brickell Biotech, Inc. (NASDAQ: BBI) Striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debili ting diseases Potential Best-in-Class Cutting-edge Experienced Hyperhidrosis Product Autoimmun

  16. Slide 16: Pipeline of NCEs with Multiple Near-Term Value Inflection Points

    Pipeline of NCEs with Multiple Near-Term Value Inflection Points Program Indication(s) Discovery Preclinical Phase | Phase II Phase Ill Approved Next Milestone Primary Axillary Mid-2022 Sofpironium Bromide Hyperhidrosis Retrometabolic Anticholinergic Commercialized in Japan: ECCLOCK® Gel 5% ) Primar

  17. Slide 17: Key Upcoming Milestones for BBI

    Key Upcoming Milestones for BBI Sofpironium HEE Bromide U.S. NDA submission for primary axillary hyperhidrosis C) er BBI-02, BBI-03, and Next Generation DYRK1A Inhibitors Initiate Phase 1 clinical Phase 1 topline results study for BBI-O2 for BBI-02 BBI-03 - Formulation development Next Generation -

  18. Slide 18: Thank You!

    ©& BrickellBio NASDAQ: BBI Thank You! Contact: IR@brickellblo.com r | Making Fresh Tracks® in Medicine October 7, 2021

Brickell Biotech — Technical Presentation (October 2021) on 6ix